Many cancer types are caused by gene fusions that bring together parts of two different genes, often changing the activity of one of the partners. Although fusion transcripts result from structural ...

Discover Editas Medicine's groundbreaking patent for enzymatically active Cas9 fusion molecules, enhancing gene editing precision with innovative nucleic acid applications.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Japanese drugmaker Eisai closed down 2.3% at 5,587 yen today, despite news of regulatory approvals for two of its drugs.

Sep. 9, 2024 — Scientists developed a highly promising gene therapy to treat glaucoma -- a debilitating eye condition that can lead to complete vision loss, and which affects around 80 million ...

TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit ...

Gene therapy, the idea of fixing faulty genes with healthy ones, has held immense promise. But a major hurdle has been finding a safe and efficient way to deliver those genes. Researchers have now ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

Genetic disorders—like cystic fibrosis and Huntington's disease—are considered incurable, with gene mutations occurring in essentially every cell of the body. Gene mutations occur when one ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to ...

Their new research is the first to comprehensively investigate the elevated expression of a gene called ZIC2 in ovarian cancer cells, finding that it is associated with poor survival rates of ...